Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114838) titled 'An observational study exploring cfDNA methylation-based biomarkers for invasiveness of pulmonary nodules' on Dec. 18, 2025.
Study Type: Diagnostic test
Study Design:
Diagnostic test for accuracy
Primary Sponsor: Beijing Cancer Hospital
Condition:
Pulmonary nodules (diameter < 30 mm)
Intervention:
Gold Standard:Histopathological diagnosis is used as the primary gold standard. Malignant pulmonary nodules must be confirmed by pathology, and classified as adenocarcinoma in situ/minimally invasive adenocarcinoma (AIS/MIA) or invasive lung cancer according to pathological findings. Benign pulmonary nodules are ...